These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9341167)

  • 1. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
    Vogt A; Sun J; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1997 Oct; 272(43):27224-9. PubMed ID: 9341167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.
    Adnane J; Bizouarn FA; Qian Y; Hamilton AD; Sebti SM
    Mol Cell Biol; 1998 Dec; 18(12):6962-70. PubMed ID: 9819384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity.
    Sun J; Qian Y; Chen Z; Marfurt J; Hamilton AD; Sebti SM
    J Biol Chem; 1999 Mar; 274(11):6930-4. PubMed ID: 10066746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
    Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts.
    Vogt A; Qian Y; McGuire TF; Hamilton AD; Sebti SM
    Oncogene; 1996 Nov; 13(9):1991-9. PubMed ID: 8934546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.
    Miquel K; Pradines A; Sun J; Qian Y; Hamilton AD; Sebti SM; Favre G
    Cancer Res; 1997 May; 57(10):1846-50. PubMed ID: 9157972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
    Kusama T; Mukai M; Tatsuta M; Matsumoto Y; Nakamura H; Inoue M
    Clin Exp Metastasis; 2003; 20(6):561-7. PubMed ID: 14598891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin.
    Lepley DM; Pelling JC
    Mol Carcinog; 1997 Jun; 19(2):74-82. PubMed ID: 9210954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome.
    Efuet ET; Keyomarsi K
    Cancer Res; 2006 Jan; 66(2):1040-51. PubMed ID: 16424040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of GGTase-I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
    Virtanen SS; Sandholm J; Yegutkin G; Kalervo Väänänen H; Härkönen PL
    Cell Biol Int; 2010 Aug; 34(8):815-26. PubMed ID: 20446922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation.
    McGuire TF; Qian Y; Vogt A; Hamilton AD; Sebti SM
    J Biol Chem; 1996 Nov; 271(44):27402-7. PubMed ID: 8910319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.
    Stark WW; Blaskovich MA; Johnson BA; Qian Y; Vasudevan A; Pitt B; Hamilton AD; Sebti SM; Davies P
    Am J Physiol; 1998 Jul; 275(1):L55-63. PubMed ID: 9688935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. X-rays induce dose-dependent and cell cycle-independent accumulation of p21(sdi1/WAF1).
    Tsuyama N; Ide T; Noda A; Iwamoto KS; Mizuno T; Kyoizumi S; Seyama T
    Hiroshima J Med Sci; 2001 Mar; 50(1):1-7. PubMed ID: 11314855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
    Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
    Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyamine depletion in human melanoma cells leads to G1 arrest associated with induction of p21WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype.
    Kramer DL; Chang BD; Chen Y; Diegelman P; Alm K; Black AR; Roninson IB; Porter CW
    Cancer Res; 2001 Nov; 61(21):7754-62. PubMed ID: 11691789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I.
    Chan LN; Fiji HD; Watanabe M; Kwon O; Tamanoi F
    PLoS One; 2011; 6(10):e26135. PubMed ID: 22028818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
    Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
    Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines.
    Chen RJ; Lee WS; Liang YC; Lin JK; Wang YJ; Lin CH; Hsieh JY; Chaing CC; Ho YS
    Toxicol Appl Pharmacol; 2000 Dec; 169(2):132-41. PubMed ID: 11097865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.